๐งฌ Cagrilintide Peptide
Overview
Cagrilintide is a long-acting amylin analog developed to help regulate appetite, body weight, and glucose metabolism. As a synthetic version of the hormone amylin, it works synergistically with GLP-1 receptor agonists like Semaglutide and Tirzepatide to amplify fat loss, increase satiety, and reduce food cravings. Currently in clinical development by Novo Nordisk, Cagrilintide shows great promise as a next-generation anti-obesity peptide.
๐ Category
Amylin Analog for Appetite Suppression, Fat Loss, and Metabolic Regulation
๐ฌ Molecular Profile
Class: Amylin analog (non-selective amylin receptor agonist)
Molecular Formula: CโโโHโโ โNโโ Oโโ Sโ
Molecular Weight: ~8576.1 g/mol
Structure: Modified analog of human amylin with enhanced stability and extended half-life
๐ What Is Cagrilintide?
Name: Cagrilintide (formerly AM833)
Type: Long-acting amylin receptor agonist
Function: Regulates appetite, gastric emptying, satiety, and food intake
Use: Being developed for obesity, weight loss, and metabolic disorders, especially in combination with GLP-1 agonists
๐งช Mechanism of Action
Cagrilintide mimics the function of amylin, a hormone co-secreted with insulin by the pancreas. It works by:
Activating amylin receptors (AMY1, AMY2, AMY3) in the brain
Enhancing satiety signals in the hypothalamus
Slowing gastric emptying, prolonging the feeling of fullness
Reducing food reward response and cravings
Supporting glucose regulation via delayed nutrient absorption
๐ฉบ Most Common Uses
โ๏ธ Potential Benefits
Fat Loss & Satiety
Enhances appetite suppression
Delays gastric emptying, increasing meal satisfaction
Targets visceral fat and central adiposity
Synergistic Stacking
Works synergistically with GLP-1 receptor agonists
May double the weight loss seen with GLP-1 monotherapy
Reduces food cravings, binge eating, and emotional hunger
Blood Sugar Regulation
Supports postprandial glucose control
Reduces rate of carbohydrate absorption
May improve insulin sensitivity when paired with GLP-1s
๐ Administration & Dosage
Delivery Forms
Injectable โ subcutaneous, administered weekly
Typical Research Dosages
๐ Scientific Research
Phase 2 Trials: Cagrilintide alone resulted in ~10% body weight reduction over 26 weeks
Combination Trials: Cagrilintide + Semaglutide led to 15.6โ17.1% weight loss, significantly outperforming Semaglutide alone
Satiety Studies: Demonstrated superior reduction in appetite and food cravings compared to placebo
Glucose Control: Improved post-meal glucose response and lowered overall calorie intake
Cagrilintide + Semaglutide is currently under evaluation in SURMOUNT and FLOW clinical programs for obesity and cardiometabolic health.
โ ๏ธ Safety & Side Effects
Common Side Effects
Nausea (usually transient, dose-dependent)
Fullness or early satiety
Mild gastrointestinal upset (bloating, gas)
Rare: constipation or diarrhea
Monitoring
Watch for excessive appetite suppression or under-eating
Consider dose titration to improve tolerability
Monitor in combination with GLP-1 agonists for enhanced effects
๐ Legal & Regulatory Status
FDA Status: Investigational โ not yet FDA-approved
Regulatory Progress: In late-stage clinical trials by Novo Nordisk
Current Availability: Not commercially available; research and clinical trial use only
โ FAQ
How is Cagrilintide different from Semaglutide?
Cagrilintide targets amylin receptors, while Semaglutide targets GLP-1 receptors. Together, they amplify appetite suppression and fat loss through complementary pathways.
Can I get Cagrilintide now?
Not yet โ it is still in clinical trials and not approved or commercially available as of 2025.
What happens when it's combined with Semaglutide?
Studies show significantly greater weight loss and satiety when combinedโpotentially up to 25% body weight reduction in longer trials.
Is it safe for long-term use?
So far, studies report mild side effects, mostly GI-related. Long-term safety is still under evaluation in current trials.
๐ Summary
Cagrilintide represents a new frontier in obesity and metabolic care, acting on amylin pathways to control appetite, slow digestion, and complement incretin-based drugs like Semaglutide and Tirzepatide. As a next-gen stacking agent, it may deliver even greater fat loss and satiety with minimal side effectsโmaking it a compound to watch in the evolving landscape of medical weight management.
Disclaimer: This content is for informational use only and does not constitute medical advice.
Sourcing
These are our vetted and trusted sources for high-quality research compounds chosen for their reliability, purity, and consistency. Shop smart, source safely.
USA & Canada
Unchained Compounds [Click Me]
Discount Code: UNCHAINED10
Discount Code: TB10
Discount Code: ROYALSAVE10
Europe
AVAILABLE SOON!
AUSTRALIA
AVAILABLE SOON!